Endorfins Capital Private Limited
Founded in 2021 and headquartered in Madhya Pradesh, India.
2021 | Indore, Madhya Pradesh (India) | Active
Endorfins Capital Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
About Endorfins Capital
Endorfins Capital Private Limited (ECPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 April 2021 (Three years and ten months 16 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ashutosh Saxena and Saxena serve as directors at the Company.
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U65999MP2021PTC055776
- Company No.
055776
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Financial Services
Who are the key members and board of directors at Endorfins Capital?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashutosh Saxena  | Director | 13-Apr-2021 | Current |
| Swati Saxena | Director | 13-Apr-2021 | Current |
Financial Performance of Endorfins Capital.
Enhance accessibility to Endorfins Capital's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Endorfins Capital?
Unlock access to Endorfins Capital's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Chameleon Traders Club Llp
Ashutosh Saxena and . Saxena are mutual person
- Sagi & Swati Trading Private Limited
Ashutosh Saxena and . Saxena are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Endorfins Capital?
Endorfins Capital has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Endorfins Capital, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Endorfins Capital's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.